Jun 13, 2024, 05:00 AM by User Not Found

Bio-IT World | Data is a double-edged sword in the industry. It is a necessary tool for technological developments, especially artificial intelligence (AI), but the excess generation of data has become a thorn on the sides of researchers and companies. And for universities, they have their own sets of problems to deal with.

Jun 12, 2024, 07:18 AM by

Integrated DNA Technologies today launched the Avian Influenza Type A (H5) Primers and Probe Set to enable researchers to identify, target, and trace the presence of clade 2.3.4.4b of the H5N1 virus across bird, environmental, dairy cow, and poultry farm samples.

Jun 12, 2024, 07:18 AM by

CluePoints Brand Evolution Confirms Commitment to ‘Turning Artificial Intelligence into Human Intelligence’ CluePoints extends its use of AI/ML and continues to find smarter ways to manage clinical trials

Jun 12, 2024, 07:18 AM by

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

Jun 12, 2024, 05:00 AM by User Not Found

Bio-IT World | When it comes to big data, the largest amount comes from whole genome sequencing (WGS). At the population scale, WGS produces petabytes of information that for sharing purposes requires cloud computing capabilities. That realization came early to UK Biobank.

Jun 11, 2024, 10:48 AM by

Exothera has announced that Asgard Therapeutics has selected them to develop and scale-up a manufacturing process for the viral vector-based immunotherapy candidate AT-108, including development of analytical methods, GMP-grade material production, and aseptic filling.

Jun 11, 2024, 05:00 AM by User Not Found

Bio-IT World | At COMPUTEX Taipei earlier this month, NVIDIA launched NIM—NVIDIA Inference Microservices—a simple, standardized way to add generative AI to applications. Data generation—rather than retrieval—is poised to take over computing.

Jun 7, 2024, 08:08 AM by

Jun 6, 2024, 09:31 AM by

Genestack has announced a collaboration with City University of New York (CUNY) to streamline data curation for the BioConductor program, a widely used open-source software project that provides tools for the analysis and comprehension of high-throughput genomic data.

Jun 6, 2024, 09:31 AM by

FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials

Jun 6, 2024, 05:00 AM by User Not Found

Bio-IT World | Ronald Realubit, Principal Scientific Business Analyst (Therapeutic Ab Development) at Regeneron, presented a map of the Regeneron team members behind the Automated High-Throughput Flow Cytometry Data Processing Pipeline project, highlighting 38 team members by name. The pipeline was one of three Regeneron projects that won a 2024 Bio-IT World Innovative Practices Award, all sharing the “Informatics to Achieve Operational Excellence” category.

Jun 5, 2024, 07:27 AM by

Jun 5, 2024, 07:26 AM by

Sinequa announces new AI Assistants; Combining Sinequa’s Search with GenAI provides the ultimate AI Assistant and virtual coworker

Jun 5, 2024, 05:00 AM by User Not Found

Bio-IT World | During his keynote address at last month’s PEGS Boston, David Liu, director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, and a Howard Hughes Medical Institute investigator, described how the laboratory evolution of gene editing systems has enabled efficient and programmable gene correction or even whole gene integration.

Jun 4, 2024, 07:46 AM by

We are pleased to announce that Limbus Medical Technologies GmbH, a medical device manufacturer and software development company based in Rostock, Germany, has reached a significant milestone in the field of genetic diagnostics. The varvis® software is now the first complete genomics software solution certified as a Class C device under the In-Vitro Diagnostic Regulation (IVDR) EU 2017/746.

Jun 4, 2024, 05:00 AM by User Not Found

Bio-IT World | The Oxford Nanopore vision was of a “new generation of single-strand sequencing technology, featuring accurate long reads of single-stranded DNA molecules,” Bio-IT World reported from the 2012 event. Today, Brown’s big ideas include whole-chromosome sequencing, flow cell loading without a pipette, and advances in chemistry, electrical engineering, and commercial format.

Jun 3, 2024, 07:31 AM by

Qlucore to receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.

May 31, 2024, 08:37 AM by

May 31, 2024, 08:37 AM by

We wanted to reach out today with some exciting, breaking news. 4D Path, a company dedicated to personalizing cancer care through their advanced approach to predicting tumor response announced this morning new clinical data regarding the efficacy of their patented Q-Plasia OncoReader (QPOR) platform, highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. "This is an exciting moment for oncology and pathology," said Stuart J. Schnitt, M.D., Chief of Breast Oncologic Pathology for the Dana-Farber Brigham Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women's Hospital Breast Oncology Program. "The 4D Path QPOR Platform can potentially help inform researchers and clinicians about which patients are more or less likely to respond to neoadjuvant chemotherapy, paving the path for more precise and personalized treatments for patients." For the first time ever, we can unveil the dynamics of the tumor microenvironment, allowing biopharma and clinicians to get more targeted and precise in the development of therapies and treatment plans. Not only that, but the profound effects this will have on clinical trials and patient stratification, the benefits to pathologists and clinicians on the front lines with patients, and to patients – not only getting more targeted treatments but also helping the people who would have not responded, more effectively get to a treatment plan that might work. This is a monumental step forward in oncology. We would love to connect you with Satabhisa Mukhopadhyay, PHD, Chief Scientific Officer and Co-Founder of 4D Path, to provide more commentary regarding the importance of this moment and how their innovative, human approach (no AI, no machine learning) is allowing us to be more effective and specific when developing and implementing treatments. We would also be happy to discuss submitting an article authored by Satabhisa discussing these topics, and connect you with industry experts like Dr. Schnitt as well. We have placed below the press release for your reference. Please let us know if you have any questions. We are always available. Look forward to hearing from you.

May 30, 2024, 08:23 AM by